What is ORGANON & CO's earnings per share (EPS)?

ORGANON & CO (OGN) reported diluted earnings per share of $0.72 for fiscal year 2025. This represents a -78.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

ORGANON & CO Financials

OGN

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows ORGANON & CO (OGN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 35/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Growth

ORGANON & CO's revenue declined 2.9% year-over-year, from $6.4B to $6.2B. This contraction results in a growth score of 28/100.

Leverage

ORGANON & CO has elevated debt relative to equity (D/E of 11.47), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.

Liquidity

ORGANON & CO's current ratio of 1.82 indicates adequate short-term liquidity, earning a score of 32/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

ORGANON & CO has a free cash flow margin of 8.7%, earning a moderate score of 47/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

ORGANON & CO earns a strong 24.9% return on equity (ROE), meaning it generates $25 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 66/100. This is down from 183.1% the prior year.

Piotroski F-Score Neutral

5/9

ORGANON & CO passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Cash-Backed

3.74x

For every $1 of reported earnings, ORGANON & CO generates $3.74 in operating cash flow ($700.0M OCF vs $187.0M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$6.2B

YoY-2.9%

5Y CAGR-1.0%

ORGANON & CO generated $6.2B in revenue in fiscal year 2025. This represents a decrease of 2.9% from the prior year.

EBITDA

N/A

Net Income

$187.0M

YoY-78.4%

5Y CAGR-38.7%

ORGANON & CO reported $187.0M in net income in fiscal year 2025. This represents a decrease of 78.4% from the prior year.

EPS (Diluted)

$0.72

YoY-78.4%

5Y CAGR-39.0%

ORGANON & CO earned $0.72 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 78.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$538.0M

YoY-29.6%

5Y CAGR-23.3%

ORGANON & CO generated $538.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 29.6% from the prior year.

Cash & Debt

$574.0M

YoY-15.0%

5Y CAGR+116.7%

ORGANON & CO held $574.0M in cash against $8.6B in long-term debt as of fiscal year 2025.

Dividends Per Share

$0.34

YoY-69.6%

ORGANON & CO paid $0.34 per share in dividends in fiscal year 2025. This represents a decrease of 69.6% from the prior year.

Shares Outstanding

260M

YoY+1.0%

ORGANON & CO had 260M shares outstanding in fiscal year 2025. This represents an increase of 1.0% from the prior year.

Margins & Returns

Gross Margin

53.3%

YoY-4.7pp

5Y CAGR-14.3pp

ORGANON & CO's gross margin was 53.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 4.7 percentage points from the prior year.

Operating Margin

N/A

Net Margin

3.0%

YoY-10.5pp

5Y CAGR-30.1pp

ORGANON & CO's net profit margin was 3.0% in fiscal year 2025, showing the share of revenue converted to profit. This is down 10.5 percentage points from the prior year.

Return on Equity

24.9%

YoY-158.2pp

5Y CAGR-14.5pp

ORGANON & CO's ROE was 24.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 158.2 percentage points from the prior year.

Capital Allocation

R&D Spending

$366.0M

YoY-22.0%

5Y CAGR+11.8%

ORGANON & CO invested $366.0M in research and development in fiscal year 2025. This represents a decrease of 22.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$162.0M

YoY-7.4%

5Y CAGR-8.7%

ORGANON & CO invested $162.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 7.4% from the prior year.

OGN Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$6.2B-2.9%	$6.4B+2.2%	$6.3B+1.4%	$6.2B-2.1%	$6.3B-3.5%	$6.5B
Cost of Revenue	$2.9B+8.0%	$2.7B+6.9%	$2.5B+9.6%	$2.3B-3.7%	$2.4B+12.4%	$2.1B
Gross Profit	$3.3B-10.8%	$3.7B-0.9%	$3.7B-3.4%	$3.9B-1.1%	$3.9B-11.1%	$4.4B
R&D Expenses	$366.0M-22.0%	$469.0M-11.2%	$528.0M+12.1%	$471.0M+6.3%	$443.0M+111.0%	$210.0M
SG&A Expenses	$1.7B-2.2%	$1.8B-7.0%	$1.9B+11.1%	$1.7B+2.2%	$1.7B+23.0%	$1.4B
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$504.0M-3.1%	$520.0M-1.3%	$527.0M+24.9%	$422.0M+63.6%	$258.0M	$0
Income Tax	$238.0M+517.5%	-$57.0M+83.7%	-$350.0M-270.7%	$205.0M+15.2%	$178.0M-64.1%	$496.0M
Net Income	$187.0M-78.4%	$864.0M-15.5%	$1.0B+11.6%	$917.0M-32.1%	$1.4B-37.5%	$2.2B
EPS (Diluted)	$0.72-78.4%	$3.33-16.5%	$3.99+11.1%	$3.59-32.4%	$5.31-37.7%	$8.52

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$1.5B-5.9%	$1.6B+0.5%	$1.6B+5.4%	$1.5B-5.0%	$1.6B+0.6%	$1.6B-1.6%	$1.6B-0.9%	$1.6B
Cost of Revenue	$766.0M+2.8%	$745.0M+3.5%	$720.0M+7.1%	$672.0M-3.4%	$696.0M+5.6%	$659.0M-1.3%	$668.0M+0.5%	$665.0M
Gross Profit	$741.0M-13.5%	$857.0M-1.9%	$874.0M+3.9%	$841.0M-6.1%	$896.0M-2.9%	$923.0M-1.7%	$939.0M-1.9%	$957.0M
R&D Expenses	$91.0M+8.3%	$84.0M-11.6%	$95.0M-1.0%	$96.0M-26.2%	$130.0M+17.1%	$111.0M-4.3%	$116.0M+3.6%	$112.0M
SG&A Expenses	$433.0M+4.3%	$415.0M-8.4%	$453.0M+7.9%	$420.0M-10.6%	$470.0M+11.4%	$422.0M-3.4%	$437.0M+1.4%	$431.0M
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$121.0M-5.5%	$128.0M-2.3%	$131.0M+5.6%	$124.0M-6.1%	$132.0M+4.8%	$126.0M-3.8%	$131.0M0.0%	$131.0M
Income Tax	$57.0M-31.3%	$83.0M-1.2%	$84.0M+500.0%	$14.0M-30.0%	$20.0M+113.2%	-$152.0M-480.0%	$40.0M+14.3%	$35.0M
Net Income	-$205.0M-228.1%	$160.0M+10.3%	$145.0M+66.7%	$87.0M-20.2%	$109.0M-69.6%	$359.0M+84.1%	$195.0M-3.0%	$201.0M
EPS (Diluted)	N/A	$0.61+8.9%	$0.56+69.7%	$0.33	N/A	$1.38+84.0%	$0.75-3.8%	$0.78

OGN Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$12.9B-1.8%	$13.1B+8.6%	$12.1B+10.1%	$11.0B+2.6%	$10.7B+5.7%	$10.1B
Current Assets	$4.4B+0.1%	$4.3B-3.5%	$4.5B+14.7%	$3.9B+4.5%	$3.8B+5.4%	$3.6B
Cash & Equivalents	$574.0M-15.0%	$675.0M-2.6%	$693.0M-1.8%	$706.0M-4.2%	$737.0M+6041.7%	$12.0M
Inventory	$1.4B+6.4%	$1.3B+0.5%	$1.3B+31.1%	$1.0B+9.6%	$915.0M+0.2%	$913.0M
Accounts Receivable	$1.3B-2.0%	$1.4B-22.1%	$1.7B+18.2%	$1.5B+6.7%	$1.4B+33.1%	$1.0B
Goodwill	$4.2B-11.3%	$4.7B+1.7%	$4.6B0.0%	$4.6B0.0%	$4.6B0.0%	$4.6B
Total Liabilities	$12.1B-4.1%	$12.6B+4.1%	$12.1B+2.4%	$11.8B-2.8%	$12.2B+163.7%	$4.6B
Current Liabilities	$2.4B-12.1%	$2.7B-6.9%	$2.9B+16.2%	$2.5B-3.3%	$2.6B-2.8%	$2.7B
Long-Term Debt	$8.6B-2.6%	$8.9B+1.2%	$8.8B-1.7%	$8.9B-2.4%	$9.1B	$0
Total Equity	$752.0M+59.3%	$472.0M+774.3%	-$70.0M+92.2%	-$892.0M+40.8%	-$1.5B-127.5%	$5.5B
Retained Earnings	$1.1B+9.8%	$1.0B+128.0%	$443.0M+233.8%	-$331.0M+66.8%	-$998.0M	$0

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$12.9B-5.1%	$13.6B+0.4%	$13.5B+2.6%	$13.2B+0.4%	$13.1B+2.7%	$12.8B+4.9%	$12.2B+2.2%	$11.9B
Current Assets	$4.4B-7.4%	$4.7B+1.8%	$4.6B+5.7%	$4.4B+0.5%	$4.3B-8.6%	$4.8B+5.5%	$4.5B+7.5%	$4.2B
Cash & Equivalents	$574.0M-14.6%	$672.0M+12.2%	$599.0M+9.5%	$547.0M-19.0%	$675.0M-11.5%	$763.0M+8.4%	$704.0M+22.4%	$575.0M
Inventory	$1.4B-5.5%	$1.5B+2.3%	$1.5B+6.8%	$1.4B+3.1%	$1.3B-4.5%	$1.4B+7.5%	$1.3B+1.9%	$1.3B
Accounts Receivable	$1.3B-10.3%	$1.5B0.0%	$1.5B+1.9%	$1.5B+7.3%	$1.4B-19.4%	$1.7B+4.2%	$1.6B+4.5%	$1.5B
Goodwill	$4.2B-11.3%	$4.7B0.0%	$4.7B0.0%	$4.7B0.0%	$4.7B+1.7%	$4.6B0.0%	$4.6B0.0%	$4.6B
Total Liabilities	$12.1B-4.2%	$12.6B-0.9%	$12.8B+1.2%	$12.6B-0.1%	$12.6B+3.0%	$12.3B+2.1%	$12.0B+1.4%	$11.8B
Current Liabilities	$2.4B-10.8%	$2.7B-4.2%	$2.8B+6.9%	$2.6B-3.8%	$2.7B-2.6%	$2.8B+1.3%	$2.8B+8.3%	$2.5B
Long-Term Debt	$8.6B-1.8%	$8.8B0.0%	$8.8B-1.7%	$8.9B+0.9%	$8.9B+1.4%	$8.7B+1.1%	$8.6B-0.7%	$8.7B
Total Equity	$752.0M-17.0%	$906.0M+23.6%	$733.0M+35.2%	$542.0M+14.8%	$472.0M-4.3%	$493.0M+242.4%	$144.0M+200.0%	$48.0M
Retained Earnings	$1.1B-15.9%	$1.3B+13.3%	$1.2B+13.4%	$1.0B+1.6%	$1.0B+3.6%	$975.0M+41.3%	$690.0M+20.4%	$573.0M

OGN Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$700.0M-25.5%	$939.0M+17.5%	$799.0M-6.9%	$858.0M-60.3%	$2.2B-5.4%	$2.3B
Capital Expenditures	$162.0M-7.4%	$175.0M-30.3%	$251.0M+28.1%	$196.0M+2.1%	$192.0M-24.7%	$255.0M
Free Cash Flow	$538.0M-29.6%	$764.0M+39.4%	$548.0M-17.2%	$662.0M-66.4%	$2.0B-3.0%	$2.0B
Investing Cash Flow	-$390.0M+24.0%	-$513.0M-97.3%	-$260.0M+38.1%	-$420.0M	N/A	N/A
Financing Cash Flow	-$561.0M-52.4%	-$368.0M+35.3%	-$569.0M-31.4%	-$433.0M	N/A	N/A
Dividends Paid	$88.0M-70.4%	$297.0M+1.0%	$294.0M+1.4%	$290.0M+100.0%	$145.0M	$0
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$141.0M-46.6%	$264.0M+20.0%	$220.0M+193.3%	$75.0M-80.8%	$390.0M+176.6%	$141.0M-57.5%	$332.0M+336.8%	$76.0M
Capital Expenditures	$45.0M-2.2%	$46.0M+17.9%	$39.0M+21.9%	$32.0M-41.8%	$55.0M+31.0%	$42.0M+31.3%	$32.0M-30.4%	$46.0M
Free Cash Flow	$96.0M-56.0%	$218.0M+20.4%	$181.0M+320.9%	$43.0M-87.2%	$335.0M+238.4%	$99.0M-67.0%	$300.0M+900.0%	$30.0M
Investing Cash Flow	-$65.0M+43.5%	-$115.0M-202.6%	-$38.0M+77.9%	-$172.0M+41.9%	-$296.0M-294.7%	-$75.0M-63.0%	-$46.0M+52.1%	-$96.0M
Financing Cash Flow	-$187.0M-146.1%	-$76.0M+65.9%	-$223.0M-197.3%	-$75.0M+8.5%	-$82.0M-5.1%	-$78.0M+41.8%	-$134.0M-81.1%	-$74.0M
Dividends Paid	$4.0M+33.3%	$3.0M-70.0%	$10.0M-85.9%	$71.0M-4.1%	$74.0M0.0%	$74.0M-6.3%	$79.0M+12.9%	$70.0M
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

OGN Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	53.3%-4.7pp	58.0%-1.8pp	59.8%-3.0pp	62.8%+0.6pp	62.2%-5.3pp	67.6%
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	3.0%-10.5pp	13.5%-2.8pp	16.3%+1.5pp	14.8%-6.6pp	21.4%-11.6pp	33.1%
Return on Equity	24.9%-158.2pp	183.1%	N/A	N/A	N/A	39.4%
Return on Assets	1.5%-5.1pp	6.6%-1.9pp	8.5%+0.1pp	8.4%-4.3pp	12.7%-8.7pp	21.4%
Current Ratio	1.82+0.2	1.60+0.1	1.54-0.0	1.56+0.1	1.45+0.1	1.33
Debt-to-Equity	11.47-7.3	18.77+143.8	-125.01-115.0	-9.98-3.9	-6.05-6.1	0.00
FCF Margin	8.7%-3.3pp	11.9%+3.2pp	8.8%-2.0pp	10.7%-20.5pp	31.2%+0.2pp	31.1%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	49.2%-4.3pp	53.5%-1.3pp	54.8%-0.7pp	55.6%-0.7pp	56.3%-2.1pp	58.3%-0.1pp	58.4%-0.6pp	59.0%
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	-13.6%-23.6pp	10.0%+0.9pp	9.1%+3.3pp	5.8%-1.1pp	6.9%-15.8pp	22.7%+10.6pp	12.1%-0.3pp	12.4%
Return on Equity	-27.3%-44.9pp	17.7%-2.1pp	19.8%+3.7pp	16.1%-7.0pp	23.1%-49.7pp	72.8%-62.6pp	135.4%-283.3pp	418.8%
Return on Assets	-1.6%-2.8pp	1.2%+0.1pp	1.1%+0.4pp	0.7%-0.2pp	0.8%-2.0pp	2.8%+1.2pp	1.6%-0.1pp	1.7%
Current Ratio	1.82+0.1	1.75+0.1	1.65-0.0	1.67+0.1	1.60-0.1	1.70+0.1	1.64-0.0	1.65
Debt-to-Equity	11.47+1.8	9.69-2.3	11.98-4.5	16.49-2.3	18.77+1.0	17.73-42.3	60.05-121.3	181.35
FCF Margin	6.4%-7.2pp	13.6%+2.2pp	11.4%+8.5pp	2.8%-18.2pp	21.0%+14.8pp	6.3%-12.4pp	18.7%+16.8pp	1.8%

Similar Companies

Grifols S A GRFS

$5.1B

Indivior Pharmaceuticals Inc. INDV

$3.5B

Bausch Health Companies Inc BHC

$1.9B

Amneal Pharmaceuticals Inc AMRX

$3.8B

Hutchmed (China) Limited HCM

$2.5B

Frequently Asked Questions

What is ORGANON & CO's annual revenue?

ORGANON & CO (OGN) reported $6.2B in total revenue for fiscal year 2025. This represents a -2.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is ORGANON & CO's revenue growing?

ORGANON & CO (OGN) revenue declined by 2.9% year-over-year, from $6.4B to $6.2B in fiscal year 2025.

Is ORGANON & CO profitable?

Yes, ORGANON & CO (OGN) reported a net income of $187.0M in fiscal year 2025, with a net profit margin of 3.0%.

How much debt does ORGANON & CO have?

As of fiscal year 2025, ORGANON & CO (OGN) had $574.0M in cash and equivalents against $8.6B in long-term debt.

What is ORGANON & CO's gross margin?

ORGANON & CO (OGN) had a gross margin of 53.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is ORGANON & CO's net profit margin?

ORGANON & CO (OGN) had a net profit margin of 3.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does ORGANON & CO pay dividends?

Yes, ORGANON & CO (OGN) paid $0.34 per share in dividends during fiscal year 2025.

What is ORGANON & CO's return on equity (ROE)?

ORGANON & CO (OGN) has a return on equity of 24.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is ORGANON & CO's free cash flow?

ORGANON & CO (OGN) generated $538.0M in free cash flow during fiscal year 2025. This represents a -29.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is ORGANON & CO's operating cash flow?

ORGANON & CO (OGN) generated $700.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are ORGANON & CO's total assets?

ORGANON & CO (OGN) had $12.9B in total assets as of fiscal year 2025, including both current and long-term assets.

What are ORGANON & CO's capital expenditures?

ORGANON & CO (OGN) invested $162.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does ORGANON & CO spend on research and development?

ORGANON & CO (OGN) invested $366.0M in research and development during fiscal year 2025.

How many shares does ORGANON & CO have outstanding?

ORGANON & CO (OGN) had 260M shares outstanding as of fiscal year 2025.

What is ORGANON & CO's current ratio?

ORGANON & CO (OGN) had a current ratio of 1.82 as of fiscal year 2025, which is generally considered healthy.

What is ORGANON & CO's debt-to-equity ratio?

ORGANON & CO (OGN) had a debt-to-equity ratio of 11.47 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is ORGANON & CO's return on assets (ROA)?

ORGANON & CO (OGN) had a return on assets of 1.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is ORGANON & CO's Piotroski F-Score?

ORGANON & CO (OGN) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are ORGANON & CO's earnings high quality?

ORGANON & CO (OGN) has an earnings quality ratio of 3.74x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is ORGANON & CO?

ORGANON & CO (OGN) scores 35 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.